Pharmacotherapy of generalized anxiety disorder: Focus and update on pregabalin

Expert Review of Neurotherapeutics

Volumn 14, Issue 1, 2014, Pages 29-38

  Both, Charlotte ^a   Kojda, Georg ^a   Lange Asschenfeldt, Christian ^a  

^a Department of Orthopedic Surgery   (Germany)

Author keywords

Anxiolytic; Drug therapy; Generalized anxiety disorder; Pregabalin; Randomized controlled trials

Indexed keywords

AGOMELATINE; ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLOMIPRAMINE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; HYDROXYZINE; IMIPRAMINE; LORAZEPAM; PAROXETINE; PREGABALIN; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BLEEDING; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; NAUSEA; NONHUMAN; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SEXUAL DYSFUNCTION; SKIN BRUISING; SLEEP DISORDER; SOMNOLENCE; SYMPTOMATOLOGY; THROMBOCYTE DYSFUNCTION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893062478     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.853617     Document Type: Review

References (77)

1. Wittchen HU, Jacobi F, Rehm J et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21(9), 655-679 (2011
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 593-602 (2005
3. Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: Diagnosis and treatment. BMJ 345, e7500 (2012). (GAD
4. Altamura AC, Dell'osso B, D'Urso N, Russo M, Fumagalli S, Mundo E. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr. 13(5), 415-422 (2008
5. Davidson JR, Feltner DE, Dugar A. Management of generalized anxiety disorder in primary care: Identifying the challenges and unmet needs. Prim. Care Companion. J. Clin. Psychiatry 12(2) (2010
6. Bandelow B, Charimo TA, Wedekind D, Broocks A, Hajak G, Ruther E. Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder. Eur. Arch. Psychiatry Clin. Neurosci 254(6), 397-405 (2004
7. Kim MJ, Loucks RA, Palmer AL et al. The structural and functional connectivity of the amygdala: Farom normal emotion to pathological anxiety. Behav. Brain Res. 223(2), 403-410 (2011
8. Andreescu C, Gross JJ, Lenze E et al. Altered cerebral blood flow patterns associated with pathologic worry in the elderly. Depress. Anxiety 28(3), 202-209 (2011
9. Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr. Scand. Suppl. (417), 38-50 (2003
10. Germine M, Goddard AW, Woods SW, Charney DS, Heninger GR. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol. Psychiatry 32(5), 457-461 (1992
11. Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics. J. 13(5), 464-469 (2012
12. Vreeburg SA, Zitman FG, van PJ et al. Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom. Med. 72(4), 340-347 (2010
13. Molina E, Cervilla J, Rivera M et al. Polymorphic variation at the serotonin 1-A receptor gene is associated with comorbid depression and generalized anxiety. Psychiatr. Genet. 21(4), 195-201 (2011
14. Bereza BG, Machado M, Ravindran AV, Einarson TR. Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder. Can. J. Psychiatry 57(8), 470-478 (2012
15. Bandelow B, Sher L, Bunevicius R et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 16(2), 77-84 (2012
16. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 14(5), 697-710 (2011
17. Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum. Psychopharmacol. 28(2), 151-159 (2013
18. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebocontrolled discontinuation study. J. Clin. Psychiatry 73(7), 1002-1008 (2012
19. Martinotti G, Sepede G, Gambi F et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: A pilot study. J. Clin. Psychopharmacol. 32(4), 487-491 (2012
20. Bossini L, Casolaro I, Koukouna D, Cecchini F, Fagiolini A. Off-label uses of trazodone: A review. Expert Opin. Pharmacother. 13(12), 1707-1717 (2012
21. Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol. Bull. 37(4), 133-146 (2003
22. Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: Acute and chronic treatment. CNS Spectr. 9(10), 716-723 (2004
23. Bandelow B, Sher L, Bunevicius R et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 16(2), 77-84 (2012
24. Huh J, Goebert D, Takeshita J, Lu BY, Kang M. Treatment of generalized anxiety disorder: A comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim. Care Companion. CNS Disord. 13(2), (2011
25. Zahreddine N, Richa S. Non-antidepressant treatment of generalized anxiety disorder. Curr. Clin. Pharmacol. (2013) (Epub ahead of print
26. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl) 139(4), 402-406 (1998
27. Buoli M, Caldiroli A, Caletti E, Paoli RA, Altamura AC. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin. Pharmacother. 14(2), 175-184 (2013
28. Aikins DE, Craske MG. Cognitive theories of generalized anxiety disorder. Psychiatr. Clin. North Am. 24(1), 57-74, vi (2001
29. Hofmann SG, Smits JA. Cognitivebehavioral therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials. J. Clin. Psychiatry 69(4), 621-632 (2008
30. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 368(9553), 2156-2166 (2006
31. Bystritsky A, Kaplan JT, Feusner JD et al. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder. J. Clin. Psychiatry 69(7), 1092-1098 (2008
32. Bystritsky A, Kerwin LE, Feusner JD. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up. J. Clin. Psychiatry 70(3), 431-432 (2009
33. Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention. Expert Rev. Neurother. 7(7), 769-781 (2007
34. Di Nicola M, Martinotti G, Tedeschi D et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum. Psychopharmacol. 25(3), 268-275 (2010
35. Martinotti G, Di NM, Frustaci A et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: A multicentre, randomized, single-blind comparison trial. Addiction 105(2), 288-299 (2010
36. Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin. Investig. Drugs 21(7), 1019-1029 (2012
37. Samuel M, Zimovetz EA, Gabriel Z, Beard SM. Efficacy and safety of treatments for refractory generalized anxiety disorder: A systematic review. Int. Clin. Psychopharmacol. 26(2), 63-68 (2011
38. Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry 9(4), 248-312 (2008
39. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: Novel modulators of neurotransmission. Trends Pharmacol. Sci. 28(2), 75-82 (2007
40. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: A novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin. Ther. 29(1), 26-48 (2007
41. Stahl SM. Mechanism of action of alpha2delta ligands: Voltage sensitive calcium channel (VSCC) modulators. J. Clin. Psychiatry 65(8), 1033-1034 (2004
42. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: A double-blind, placebo-controlled trial. J. Psychopharmacol. 26(4), 461-470 (2012
43. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin. Pharmacokinet. 49(10), 661-669 (2010
44. Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: Does a fetal accumulation occur during pregnancy? Epilepsia 46(10), 1621-1624 (2005
45. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin. Pharmacokinet. 46(3), 209-219 (2007
46. Dworkin RH, Corbin AE, Young JP Jr et al. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 60(8), 1274-1283 (2003
47. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 43(3), 277-283 (2003
48. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 40(4), 163-168 (2007
49. Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebocontrolled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 23(3), 240-249 (2003
50. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6-week, multicenter, randomized, double-blind, placebocontrolled comparison of pregabalin and venlafaxine. J. Clin. Psychiatry 67(5), 771-782 (2006
51. Kasper S, Herman B, Nivoli G et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: Results of a double-blind, placebo-controlled 8-week trial. Int. Clin. Psychopharmacol. 24(2), 87-96 (2009
52. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int. Clin. Psychopharmacol. 23(1), 18-28 (2008
53. Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: Results of a double-blind, placebo-controlled 26-week study. Int. Clin. Psychopharmacol. 26(5), 243-251 (2011
54. Rickels K, Pollack MH, Feltner DE et al. Pregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry 62(9), 1022-1030 (2005
55. Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am. J. Psychiatry 160(3), 533-540 (2003
56. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysis. BMJ 342, d1199 (2011
57. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies. Eur. Neuropsychopharmacol. 18(6), 422-430 (2008
58. Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 13(2), 229-241 (2010
59. Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int. Clin. Psychopharmacol. 27(3), 142-150 (2012
60. Cabrera J, Emir B, Dills D, Murphy TK, Whalen E, Clair A. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr. Med. Res. Opin. 28(6), 1027-1037 (2012
61. Ogawa S, Satoh J, Arakawa A, Yoshiyama T, Suzuki M. Pregabalin treatment for peripheral neuropathic pain: A review of safety data from randomized controlled trials conducted in Japan and in the west. Drug Saf. 35(10), 793-806 (2012
62. Hoppe C, Rademacher M, Hoffmann JM, Schmidt D, Elger CE. Bodyweight gain under pregabalin therapy in epilepsy: Mitigation by counseling patients? Seizure 17(4), 327-332 (2008
63. Criswell KA, Cook JC, Wojcinski Z et al. Mode of action associated with development of hemangiosarcoma in mice given pregabalin and assessment of human relevance. Toxicol. Sci. 128(1), 57-71 (2012
64. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: Double-blind, placebo-controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol. 25(2), 151-158 (2005
65. Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J. Am. Osteopath. Assoc. 110(10), 605-607 (2010
66. Grosshans M, Mutschler J, Hermann D et al. Pregabalin abuse, dependence, and withdrawal: A case report. Am. J. Psychiatry 167(7), 869 (2010
67. Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur. J. Clin. Pharmacol. 66(9), 947-953 (2010
68. Schifano F, D'Offizi S, Piccione M et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother. Psychosom. 80(2), 118-122 (2011
69. Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: Results from a database query. Eur. J. Clin. Pharmacol. 69(6), 1335-1342 (2013
70. Goodwin RD, Stein DJ. Anxiety disorders and drug dependence: Evidence on sequence and specificity among adults. Psychiatry Clin. Neurosci. 67(3), 167-173 (2013
71. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress. Anxiety 25(1), 72-90 (2008
72. Silva ML, Silva MN, Ines M. A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. Cost Eff. Resour. Alloc. 11(1), 8 (2013
73. Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G. Costeffectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: Faindings from a Spanish perspective. Eur. J. Health Econ. 11(1), 35-44 (2010
74. De Salas-Cansado M, Olivares JM, Alvarez E, Carrasco JL, Barrueta A, Rejas J. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: A post hoc cost-effectiveness analysis in usual medical practice in Spain. Clinicoecon. Outcomes Res. 4, 157-168 (2012
75. De Salas-Cansado M, Alvarez E, Olivares JM, Carrasco JL, Ferro MB, Rejas J. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain. Soc. Psychiatry Psychiatr. Epidemiol. 48(6), 985-996 (2013
76. Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 354(12), 1243-1252 (2006
77. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br. J. Psychiatry 193(5), 389-394 (2008